The Pharming Group NV has confirmed plans to submit a new marketing authorisation application for its lead drug, Rhucin, to the European Medicines Agency in September 2009 and thereafter, to the US Food and Drug Administration.
Novartis AG reported net income of $4 billion at the 2009 first half and confirmed its forecast for a “strong operational performance” for the year as a whole. The company also said its cancer therapy, Afinitor, should be approved in the EU soon.
BTG Plc said that it is moving ahead with plans to set up a US hospital sales force to sell two emergency-care products acquired at the time of its takeover of Protherics Plc in 2008. It is also looking for in-licensing opportunities.
Wilex AG said that its portfolio of cancer products should reach some important thresholds in 2009. One likely threshold would be the start of a first-in-man trial of a kinase inhibitor which would result in a milestone payment from UCB Pharma SA.
The European Commission has opened antitrust investigations against Servier, one of France’s largest pharmaceutical companies, and a number of generic manufacturers for suspected breaches of EU competition law. These are the first proceedings to be brought after its 18-month pharma industry probe.
Lundbeck A/S, which has a global franchise in drugs for the central nervous system, has acquired LifeHealth Ltd of the UK to increase its interest in the neurological drug, Xenazine (tetrabenazine), which was launched in the US in late 2008.
Novacta Biosystems Ltd, which is developing a class of naturally-derived antibiotics, will receive up to £13.1 million in equity financing for the development of its portfolio, provided certain undisclosed milestones are met.
MorphoSys AG said that it has received a commitment from Novartis to complete a ten-year alliance which aims to discover and develop antibodies against several molecular targets in a wide range of diseases.
Elan Corporation Plc has reached an agreement with Johnson & Johnson that will give the US multinational an 18.4% stake in the company as well as controlling interest in a new unit that will hold many of Elan’s assets in Alzheimer’s disease.
Sanofi-aventis has become the latest multinational pharmaceutical company to decentralise its research and development business in order to generate more ideas for new drugs from contact with scientists and entrepreneurs outside the company.